The DOI matches its Crossref record; 471 of the 471 references it cites were found in a registry or an index.
Vascular Dysfunction in Alzheimer’s Disease: A Prelude to the Pathological Process or a Consequence of It?
Open accessAbstract
Alzheimer’s disease (AD) is the most prevalent form of dementia. Despite decades of research following several theoretical and clinical lines, all existing treatments for the disorder are purely symptomatic. AD research has traditionally been focused on neuronal and glial dysfunction. Although there is a wealth of evidence pointing to a significant vascular component in the disease, this angle has been relatively poorly explored. In this review, we consider the various aspects of vascular dysfunction in AD, which has a significant impact on brain metabolism and homeostasis and the clearance of β-amyloid and other toxic metabolites. This may potentially precede the onset of the hallmark pathophysiological and cognitive symptoms of the disease. Pathological changes in vessel haemodynamics, angiogenesis, vascular cell function, vascular coverage, blood-brain barrier permeability and immune cell migration may be related to amyloid toxicity, oxidative stress and apolipoprotein E (APOE) genotype. These vascular deficits may in turn contribute to parenchymal amyloid deposition, neurotoxicity, glial activation and metabolic dysfunction in multiple cell types. A vicious feedback cycle ensues, with progressively worsening neuronal and vascular pathology through the course of the disease. Thus, a better appreciation for the importance of vascular dysfunction in AD may open new avenues for research and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pericyte loss influences Alzheimer-like neurodegeneration in mice
Sagare, A. P., Bell, R. D., Zhao, Z., Ma, Q., Winkler, E. A., Ramanathan, A., & Zlokovic, B. V. (2013) · Nature Communications · doi:10.1038/ncomms3932 · Cited by 589
RetractedNIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
Monocyte Chemoattractant Protein-1 (MCP-1): An Overview
Deshmane, S. L., Kremlev, S., Amini, S., & Sawaya, B. E. (2009) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2008.0027 · Cited by 3,889
Cognitive reserve in ageing and Alzheimer's disease
Stern, Y. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70191-6 · Cited by 3,557 · cited 1×
“Cognitive reserve may result in the preservation of cognitive function until a critical mass of neuronal loss has been achieved [101].”
BackgroundMills, K. T., Bundy, J. D., Kelly, T. N., Reed, J. E., Kearney, P. M., Reynolds, K., Chen, J., & He, J. (2016) · Circulation · doi:10.1161/circulationaha.115.018912 · Cited by 3,531
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Pericytes regulate the blood–brain barrier
Armulik, A., Genové, G., Mäe, M., Nisancioglu, M. H., Wallgard, E., Niaudet, C., He, L., Norlin, J., Lindblom, P., Strittmatter, K., et al. (2010) · Nature · doi:10.1038/nature09522 · Cited by 2,843
Ignotz, R. A., & Massagué, J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35666-1 · Cited by 2,492
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 1×
“The cholinergic hypothesis is based on the observation that post-mortem AD brains exhibit severely decreased cholinergic innervation in several brain regions, in particular the temporal cortex and hippocampus [102].”
BackgroundBlood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 1×
“Bapineuzumab is a humanized mouse monoclonal antibody against Aβ, believed to induce the BBB-mediated clearance of Aβ and uptake by microglia in a dose-dependent manner [465,466].”
BackgroundRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935 · cited 3×
“Activated microglia likely play a protective role in the AD brain, being found around Aβ plaques and possibly being involved in their immunological isolation from the surrounding parenchyma [209,210].”
BackgroundInfluentialCapillary pericytes regulate cerebral blood flow in health and disease
Hall, C. N., Reynell, C., Gesslein, B., Hamilton, N. B., Mishra, A., Sutherland, B. A., O’Farrell, F. M., Buchan, A. M., Lauritzen, M., & Attwell, D. (2014) · Nature · doi:10.1038/nature13165 · Cited by 1,870
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
Vascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Distinct patterns of brain activity in young carriers of the APOE -ε4 allele
Filippini, N., MacIntosh, B. J., Hough, M. G., Goodwin, G. M., Frisoni, G. B., Smith, S. M., Matthews, P. M., Beckmann, C. F., & Mackay, C. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811879106 · Cited by 1,613
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Brain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293 · cited 2×
“Meanwhile, unlike APOE3, APOE4 appears not to suppress this pathway, resulting in greater cerebrovascular injury [220].”
BackgroundMidlife cardiovascular risk factors and risk of dementia in late life
Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C., & Yaffe, K. (2005) · Neurology · doi:10.1212/01.wnl.0000149519.47454.f2 · Cited by 1,238
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220
Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207
Bidirectional control of CNS capillary diameter by pericytes
Peppiatt, C. M., Howarth, C., Mobbs, P., & Attwell, D. (2006) · Nature · doi:10.1038/nature05193 · Cited by 1,150
O'Brien, J. T., & Thomas, A. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00463-8 · Cited by 1,136
Smith, C. W., Marlin, S. D., Rothlein, R., Toman, C., & Anderson, D. C. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114111 · Cited by 1,092
ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050
Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences
Mielke, M., Vemuri, P., & Rocca, W. (2014) · Clinical Epidemiology · doi:10.2147/clep.s37929 · Cited by 1,021
Oosthuyse, B., Moons, L., Storkebaum, E., Beck, H., Nuyens, D., Brusselmans, K., Dorpe, J. V., Hellings, P., Gorselink, M., Heymans, S., et al. (2001) · Nature Genetics · doi:10.1038/88842 · Cited by 1,007
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975
Silverman, D. H. S., Small, G. W., Chang, C. Y., Lu, C. S., de Aburto, M. A. K., Chen, W., Czernin, J., Rapoport, S. I., Pietrini, P., Alexander, G. E., et al. (2001) · JAMA · doi:10.1001/jama.286.17.2120 · Cited by 951
Mosconi, L. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1762-7 · Cited by 898
Sex modifies the APOE ‐related risk of developing Alzheimer disease
Altmann, A., Tian, L., Henderson, V. W., Greicius, M. D., & Alzheimer's Disease Neuroimaging Initiative Investigators (2014) · Annals of Neurology · doi:10.1002/ana.24135 · Cited by 891
Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867
Neutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin
Zenaro, E., Pietronigro, E., Bianca, V. D., Piacentino, G., Marongiu, L., Budui, S., Turano, E., Rossi, B., Angiari, S., Dusi, S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3913 · Cited by 865 · cited 3×
“Soluble Aβ1-42 administration causes neutrophils to rapidly adhere to the endothelium through ICAM-1, mediated by lymphocyte function-associated antigen-1 (LFA-1) [216].”
BackgroundInfluentialNeurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease
Bell, R. D., & Zlokovic, B. V. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0522-3 · Cited by 860
Estrogen Deficiency and Risk of Alzheimer's Disease in Women
Paganini-Hill, A., & Henderson, V. W. (1994) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117244 · Cited by 853
LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Aggregation of vascular risk factors and risk of incident Alzheimer disease
Luchsinger, J. A., Reitz, C., Honig, L. S., Tang, M. X., Shea, S., & Mayeux, R. (2005) · Neurology · doi:10.1212/01.wnl.0000172914.08967.dc · Cited by 790
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771
Neurovascular mechanisms of Alzheimer's neurodegeneration
Zlokovic, B. V. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.02.001 · Cited by 770
Inai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 757
Gao, S., Hendrie, H. C., Hall, K. S., & Hui, S. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.9.809 · Cited by 754
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753 · cited 1×
“APOE4 carriers, on the other hand, did not benefit from treatment and were at additional risk for vasogenic cerebral edema [466,467].”
BackgroundRetinal angiogenesis in development and disease
Gariano, R. F., & Gardner, T. W. (2005) · Nature · doi:10.1038/nature04482 · Cited by 705
β-Amyloid-mediated vasoactivity and vascular endothelial damage
Thomas, T., Thomas, G., McLendon, C., Sutton, T., & Mullan, M. (1996) · Nature · doi:10.1038/380168a0 · Cited by 703
GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration
Winkler, E. A., Nishida, Y., Sagare, A. P., Rege, S. V., Bell, R. D., Perlmutter, D., Sengillo, J. D., Hillman, S., Kong, P., Nelson, A. R., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.3966 · Cited by 689
Vascular endothelial growth factor: Direct neuroprotective effect in in vitro ischemia
Jin, K. L., Mao, X. O., & Greenberg, D. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.18.10242 · Cited by 684
Weller, R. O., Subash, M., Preston, S. D., Mazanti, I., & Carare, R. O. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00133.x · Cited by 681
Weller, R. O., Massey, A., Newman, T. A., Hutchings, M., Kuo, Y.-M., & Roher, A. E. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65616-7 · Cited by 679
Halliday, M. R., Rege, S. V., Ma, Q., Zhao, Z., Miller, C. A., Winkler, E. A., & Zlokovic, B. V. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.44 · Cited by 649
Glial Cells Dilate and Constrict Blood Vessels: A Mechanism of Neurovascular Coupling
Metea, M. R., & Newman, E. A. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4048-05.2006 · Cited by 638
Age, APOE and sex: triad of risk of Alzheimer’s disease.
Riedel, B. C., Thompson, P. M., & Brinton, R. D. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.012 · Cited by 627
Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders
Jucker, M., & Walker, L. C. (2011) · Annals of Neurology · doi:10.1002/ana.22615 · Cited by 622 · cited 1×
“However, given recent interest in pathogenic Aβ seeding and the spread of amyloid pathology in the AD brain [300], this is an area that could provide some interesting insights into the involvement of the AD vasculature in the early generation and spread of amyloid pathology.”
BackgroundSmall, G. W. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520360056039 · Cited by 604
TGF-β signaling in vascular biology and dysfunction
Goumans, M.-J., Liu, Z., & ten Dijke, P. (2009) · Cell Research · doi:10.1038/cr.2008.326 · Cited by 601
Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease
van de Haar, H. J., Burgmans, S., Jansen, J. F. A., van Osch, M. J. P., van Buchem, M. A., Muller, M., Hofman, P. A. M., Verhey, F. R. J., & Backes, W. H. (2016) · Radiology · doi:10.1148/radiol.2016152244 · Cited by 601
Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells.
Goldgaber, D., Harris, H. W., Hla, T., Maciag, T., Donnelly, R. J., Jacobsen, J. S., Vitek, M. P., & Gajdusek, D. C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7606 · Cited by 595
Johnson, N. A., Jahng, G.-H., Weiner, M. W., Miller, B. L., Chui, H. C., Jagust, W. J., Gorno-Tempini, M. L., & Schuff, N. (2005) · Radiology · doi:10.1148/radiol.2343040197 · Cited by 587
Arvanitakis, Z., Capuano, A. W., Leurgans, S. E., Bennett, D. A., & Schneider, J. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30029-1 · Cited by 581
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
van Dyck, C. H. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.010 · Cited by 568
The neurovascular unit - concept review
Muoio, V., Persson, P. B., & Sendeski, M. M. (2014) · Acta Physiologica · doi:10.1111/apha.12250 · Cited by 564
Ellis, R. J., Olichney, J. M., Thal, L. J., Mirra, S. S., Morris, J. C., Beekly, D., & Heyman, A. (1996) · Neurology · doi:10.1212/wnl.46.6.1592 · Cited by 561
Sengillo, J. D., Winkler, E. A., Walker, C. T., Sullivan, J. S., Johnson, M., & Zlokovic, B. V. (2013) · Brain Pathology · doi:10.1111/bpa.12004 · Cited by 553
Deane, R., Bell, R., Sagare, A., & Zlokovic, B. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601867 · Cited by 548
Alzheimer's disease: Focal cortical changes shown by positron emission tomography
Foster, N. L., Chase, T. N., Fedio, P., Patronas, N. J., Brooks, R. A., & Chiro, G. D. (1983) · Neurology · doi:10.1212/wnl.33.8.961 · Cited by 540
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core
Jagust, W. J., Bandy, D., Chen, K., Foster, N. L., Landau, S. M., Mathis, C. A., Price, J. C., Reiman, E. M., Skovronsky, D., Koeppe, R. A., et al. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.03.003 · Cited by 533
González-Reyes, R. E., Nava-Mesa, M. O., Vargas-Sánchez, K., Ariza-Salamanca, D., & Mora-Muñoz, L. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00427 · Cited by 527
RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease
Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A., Silverberg, G. D., Miller, M. C., Tavares, R., Yang, W., Wu, Q., Sabo, E., et al. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0115-3 · Cited by 519
Simpson, I. A., Chundu, K. R., Davies‐Hill, T., Honer, W. G., & Davies, P. (1994) · Annals of Neurology · doi:10.1002/ana.410350507 · Cited by 490
Microvascular injury and blood–brain barrier leakage in Alzheimer's disease
Zipser, B. D., Johanson, C. E., Gonzalez, L., Berzin, T. M., Tavares, R., Hulette, C. M., Vitek, M. P., Hovanesian, V., & Stopa, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.016 · Cited by 487
Preclinical prediction of Alzheimer's disease using SPECT
Johnson, K. A., Jones, K., Holman, B. L., Becker, J. A., Spiers, P. A., Satlin, A., & Albert, M. S. (1998) · Neurology · doi:10.1212/wnl.50.6.1563 · Cited by 471 · cited 3×
“It was shown that prior to clinical AD onset, hypoperfusion in the hippocampus, amygdala, posterior cingulate gyrus and left anterior thalamus precedes deficits in the temporoparietal cortex [75].”
BackgroundResultOverlap Between Pathology of Alzheimer Disease and Vascular Dementia
Kalaria, R. N., & Ballard, C. (1999) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199912003-00017 · Cited by 470
Friedland, R. P., Budinger, T. F., Ganz, E., Yano, Y., Mathis, C. A., Koss, B., Ober, B. A., Huesman, R. H., & Derenzo, S. E. (1983) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-198308000-00003 · Cited by 468
Pericytes support neutrophil subendothelial cell crawling and breaching of venular walls in vivo
Proebstl, D., Voisin, M.-B., Woodfin, A., Whiteford, J., D’Acquisto, F., Jones, G. E., Rowe, D., & Nourshargh, S. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111622 · Cited by 467
Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease
Yamazaki, Y., & Kanekiyo, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091965 · Cited by 451
Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448 · cited 1×
“Another two anti-Aβ mABs are currently in clinical trials—BAN2401, selective for Aβ protofibrils [447,448] and gantenerumab, selective for a specific folded conformation of aggregated Aβ [449].”
BackgroundStark, K., Eckart, A., Haidari, S., Tirniceriu, A., Lorenz, M., von Brühl, M.-L., Gärtner, F., Khandoga, A. G., Legate, K. R., Pless, R., et al. (2013) · Nature Immunology · doi:10.1038/ni.2477 · Cited by 447
Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia.
Graham, N. L., Emery, T., & Hodges, J. R. (2004) · PubMed · Cited by 447
Two Types of Sporadic Cerebral Amyloid Angiopathy
Thal, D. R., Ghebremedhin, E., Rüb, U., Yamaguchi, H., Del Tredici, K., & Braak, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.3.282 · Cited by 446
Clinical features of Alzheimer's disease
Förstl, H., & Kurz, A. (1999) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060050101 · Cited by 442
Chartier-Hariln, M.-C., Parfitt, M., Legrain, S., Pérez-Tur, J., Brousseau, T., Evans, A., Berr, C., Vldal, O., Roques, P., Gourlet, V., et al. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.4.569 · Cited by 438
New Acetylcholinesterase Inhibitors for Alzheimer's Disease
Mehta, M., Adem, A., & Sabbagh, M. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/728983 · Cited by 436
Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease
Wyss-Coray, T., Masliah, E., Mallory, M., McConlogue, L., Johnson-Wood, K., Lin, C., & Mucke, L. (1997) · Nature · doi:10.1038/39321 · Cited by 417 · cited 29×
“In addition, the co-occurrence of CAA and hypertension in AD patients may increase the risk of cerebral infarction [265].”
BackgroundInfluentialCentral role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance
Zhao, Z., Sagare, A. P., Ma, Q., Halliday, M. R., Kong, P., Kisler, K., Winkler, E. A., Ramanathan, A., Kanekiyo, T., Bu, G., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4025 · Cited by 410
Ryu, J. K., & McLarnon, J. G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00434.x · Cited by 406
SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein
Iadecola, C., Zhang, F., Niwa, K., Eckman, C., Turner, S. K., Fischer, E., Younkin, S., Borchelt, D. R., Hsiao, K. K., & Carlson, G. A. (1999) · Nature Neuroscience · doi:10.1038/5715 · Cited by 399
FDG PET imaging in patients with pathologically verified dementia.
Hoffman, J. M., Welsh-Bohmer, K. A., Hanson, M., Crain, B. J., Hulette, C. M., Earl, N., & Coleman, R. E. (2000) · PubMed · Cited by 399
Dai, W., Lopez, O. L., Carmichael, O. T., Becker, J. T., Kuller, L. H., & Gach, H. M. (2009) · Radiology · doi:10.1148/radiol.2503080751 · Cited by 398
Relation of Plasma Lipids to Alzheimer Disease and Vascular Dementia
Reitz, C., Tang, M.-X., Luchsinger, J., & Mayeux, R. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.705 · Cited by 397
The Fluorodeoxyglucose 18F Scan in Alzheimer's Disease and Multi-infarct Dementia
Benson, D. F., Kuhl, D. E., Hawkins, R. A., Phelps, M. E., Cummings, J. L., & Tsai, S. Y. (1983) · Archives of Neurology · doi:10.1001/archneur.1983.04050110029003 · Cited by 392
GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier
Seidner, G., Alvarez, M. G., Yeh, J.-I., O'Driscoll, K. R., Klepper, J., Stump, T. S., Wang, D., Spinner, N. B., Birnbaum, M. J., & De Vivo, D. C. (1998) · Nature Genetics · doi:10.1038/ng0298-188 · Cited by 386
Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review
Reitz, C. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/369808 · Cited by 376
Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease
Mesulam, M. ‐. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23415 · Cited by 375
Davis, J., Xu, F., Deane, R., Romanov, G., Previti, M. L., Zeigler, K., Zlokovic, B. V., & Van Nostrand, W. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312946200 · Cited by 373
Clearance of amyloid-β by circulating lipoprotein receptors
Sagare, A., Deane, R., Bell, R. D., Johnson, B., Hamm, K., Pendu, R., Marky, A., Lenting, P. J., Wu, Z., Zarcone, T., et al. (2007) · Nature Medicine · doi:10.1038/nm1635 · Cited by 373
Blood-Brain Barrier Tight Junction Disruption in Human Immunodeficiency Virus-1 Encephalitis
Dallasta, L. M., Pisarov, L. A., Esplen, J. E., Werley, J. V., Moses, A. V., Nelson, J. A., & Achim, C. L. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65511-3 · Cited by 372
Cortical abnormalities in Alzheimer's disease
Foster, N. L., Chase, T. N., Mansi, L., Brooks, R., Fedio, P., Patronas, N. J., & Di Chiro, G. (1984) · Annals of Neurology · doi:10.1002/ana.410160605 · Cited by 372
Estrogen use, APOE, and cognitive decline: Evidence of gene–environment interaction
Yaffe, K., Haan, M., Byers, A., Tangen, C., & Kuller, L. (2000) · Neurology · doi:10.1212/wnl.54.10.1949 · Cited by 371
Can disturbed brain microcirculation cause Alzheimer’s disease?
de la Torre, J. C., & Mussivan, T. (1993) · Neurological Research · doi:10.1080/01616412.1993.11740127 · Cited by 365
Tarkowski, E., Issa, R., Sjögren, M., Wallin, A., Blennow, K., Tarkowski, A., & Kumar, P. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00285-8 · Cited by 360
Blood–spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis
Winkler, E. A., Sengillo, J. D., Sullivan, J. S., Henkel, J. S., Appel, S. H., & Zlokovic, B. V. (2013) · Acta Neuropathologica · doi:10.1007/s00401-012-1039-8 · Cited by 354 · cited 1×
“Pericytes play an important role in the maintenance of BBB integrity and pericyte loss has been directly implicated in BBB breakdown in AD and other disorders like amyotrophic lateral sclerosis (ALS) [183,188].”
BackgroundBlood—Brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model
UJIIE, M., DICKSTEIN, D. L., CARLOW, D. A., & JEFFERIES, W. A. (2003) · Microcirculation · doi:10.1038/sj.mn.7800212 · Cited by 351
Intracellular Pool of Vascular Endothelial Growth Factor in Human Neutrophils
Gaudry, M., Brégerie, O., Andrieu, V., El Benna, J., Pocidalo, M.-A., & Hakim, J. (1997) · Blood · doi:10.1182/blood.v90.10.4153 · Cited by 345
Guijarro-Muñoz, I., Compte, M., Álvarez-Cienfuegos, A., Álvarez-Vallina, L., & Sanz, L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.521161 · Cited by 342
Cortes-Canteli, M., Paul, J., Norris, E. H., Bronstein, R., Ahn, H. J., Zamolodchikov, D., Bhuvanendran, S., Fenz, K. M., & Strickland, S. (2010) · Neuron · doi:10.1016/j.neuron.2010.05.014 · Cited by 339
Reduced Glucose Transporter at the Blood‐Brain Barrier and in Cerebral Cortex in Alzheimer Disease
Kalaria, R. N., & Harik, S. I. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07399.x · Cited by 338
Cardiovascular disease and Alzheimer's disease: common links
STAMPFER, M. J. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01687.x · Cited by 324
Fischer, S., Wobben, M., Marti, H. H., Renz, D., & Schaper, W. (2002) · Microvascular Research · doi:10.1006/mvre.2001.2367 · Cited by 316
Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage
Shafiei, S. S., Guerrero-Muñoz, M. J., & Castillo-Carranza, D. L. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00083 · Cited by 314
Fiala, M., Liu, Q. N., Sayre, J., Pop, V., Brahmandam, V., Graves, M. C., & Vinters, H. V. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.00994.x · Cited by 307
Irie, F., Fitzpatrick, A. L., Lopez, O. L., Kuller, L. H., Peila, R., Newman, A. B., & Launer, L. J. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.29 · Cited by 305
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends
Bachurin, S. O., Bovina, E. V., & Ustyugov, A. A. (2017) · Medicinal Research Reviews · doi:10.1002/med.21434 · Cited by 304
Biron, K. E., Dickstein, D. L., Gopaul, R., & Jefferies, W. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023789 · Cited by 300
Jaturapatporn, D., Isaac, M. G. E. K. N., McCleery, J., & Tabet, N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006378.pub2 · Cited by 299
Bennett, R. E., Robbins, A. B., Hu, M., Cao, X., Betensky, R. A., Clark, T., Das, S., & Hyman, B. T. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710329115 · Cited by 299
Aberrant insulin signaling in Alzheimer's disease: current knowledge
Bedse, G., Di Domenico, F., Serviddio, G., & Cassano, T. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00204 · Cited by 292
Inflammatory factors are elevated in brain microvessels in Alzheimer's disease
Grammas, P. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00276-7 · Cited by 291
Niwa, K., Kazama, K., Younkin, L., Younkin, S. G., Carlson, G. A., & Iadecola, C. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00022.2002 · Cited by 286
Rocca, W. A., Grossardt, B. R., & Shuster, L. T. (2011) · Brain Research · doi:10.1016/j.brainres.2010.10.031 · Cited by 283
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease
Farlow, M., Arnold, S. E., van Dyck, C. H., Aisen, P. S., Snider, B. J., Porsteinsson, A. P., Friedrich, S., Dean, R. A., Gonzales, C., Sethuraman, G., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.09.224 · Cited by 280
Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease
Wu, Z., Guo, H., Chow, N., Sallstrom, J., Bell, R. D., Deane, R., Brooks, A. I., Kanagala, S., Rubio, A., Sagare, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1287 · Cited by 280
Nishitsuji, K., Hosono, T., Nakamura, T., Bu, G., & Michikawa, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.225532 · Cited by 275 · cited 1×
“In an in vitro BBB model reconstituted with APOE4-positive mouse astrocytes, tight junction deficits were observed, including reduced phosphorylation of occludin [218].”
BackgroundTucker, S., Möller, C., Tegerstedt, K., Lord, A., Laudon, H., Sjödahl, J., Söderberg, L., Spens, E., Sahlin, C., Waara, E. R., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140741 · Cited by 272 · cited 1×
“Another two anti-Aβ mABs are currently in clinical trials—BAN2401, selective for Aβ protofibrils [447,448] and gantenerumab, selective for a specific folded conformation of aggregated Aβ [449].”
BackgroundTOKUDA, T., CALERO, M., MATSUBARA, E., VIDAL, R., KUMAR, A., PERMANNE, B., ZLOKOVIC, B., SMITH, J. D., LADU, M. J., ROSTAGNO, A., et al. (2000) · Biochemical Journal · doi:10.1042/bj3480359 · Cited by 272
Neuropathological evaluation of mixed dementia
Jellinger, K. A., & Attems, J. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.045 · Cited by 272
Matsuzaki, H., Tamatani, M., Yamaguchi, A., Namikawa, K., Kiyama, H., Vitek, M. P., Mitsuda, N., & Tohyama, M. (2001) · The FASEB Journal · doi:10.1096/fj.00-0495fje · Cited by 271
Proinflammatory Mediators Stimulate Neutrophil-Directed Angiogenesis
McCourt, M. (1999) · Archives of Surgery · doi:10.1001/archsurg.134.12.1325 · Cited by 268
Alzheimer's disease and angiogenesis
Vagnucci, A. H., & Li, W. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12521-4 · Cited by 266
Kook, S.-Y., Hong, H. S., Moon, M., Ha, C. M., Chang, S., & Mook-Jung, I. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.6102-11.2012 · Cited by 265
Di Marco, L. Y., Venneri, A., Farkas, E., Evans, P. C., Marzo, A., & Frangi, A. F. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.014 · Cited by 262
Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias
Yarchoan, M., Xie, S. X., Kling, M. A., Toledo, J. B., Wolk, D. A., Lee, E. B., Van Deerlin, V., Lee, V. M. Y., Trojanowski, J. Q., & Arnold, S. E. (2012) · Brain · doi:10.1093/brain/aws271 · Cited by 262
SRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells
Bell, R. D., Deane, R., Chow, N., Long, X., Sagare, A., Singh, I., Streb, J. W., Guo, H., Rubio, A., Van Nostrand, W., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1819 · Cited by 261
Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease
Meyer, E. P., Ulmann-Schuler, A., Staufenbiel, M., & Krucker, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709788105 · Cited by 260
Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease
Chen, Y., Wolk, D. A., Reddin, J. S., Korczykowski, M., Martinez, P. M., Musiek, E. S., Newberg, A. B., Julin, P., Arnold, S. E., Greenberg, J. H., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31823a0ef7 · Cited by 259
Similarities between Alzheimer's disease and vascular dementia
Kalaria, R. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00256-3 · Cited by 259
Forloni, G., Demicheli, F., Giorgi, S., Bendotti, C., & Angeretti, N. (1992) · Molecular Brain Research · doi:10.1016/0169-328x(92)90202-m · Cited by 256
SPECT perfusion imaging in the diagnosis of Alzheimer’s disease: A clinical-pathologic study
Jagust, W., Thisted, R., Devous, M. D., Van Heertum, R., Mayberg, H., Jobst, K., Smith, A. D., & Borys, N. (2001) · Neurology · doi:10.1212/wnl.56.7.950 · Cited by 255
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease
Cummings, J. L., Cohen, S., van Dyck, C. H., Brody, M., Curtis, C., Cho, W., Ward, M., Friesenhahn, M., Rabe, C., Brunstein, F., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005550 · Cited by 252
The neurovascular unit in brain function and disease: The neurovascular unit function
Lecrux, C., & Hamel, E. (2011) · Acta Physiologica · doi:10.1111/j.1748-1716.2011.02256.x · Cited by 251 · cited 1×
“The release of such agents in particular by interneurons and astrocytes allows for the rapid and precise modulation of blood flow as well as vascular cell function and homeostasis in response to local metabolic demand [171].”
BackgroundKennedy, A. M., Frackowiak, R. S. J., Newman, S. K., Bloomfield, P. M., Seaward, J., Roques, P., Lewington, G., Cunningham, V. J., & Rossor, M. N. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11270-7 · Cited by 250
Olichney, J. M., Hansen, L. A., Hofstetter, C. R., Grundman, M., Katzman, R., & Thal, L. J. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540310076019 · Cited by 246
Aβ1–40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation
Niwa, K., Younkin, L., Ebeling, C., Turner, S. K., Westaway, D., Younkin, S., Ashe, K. H., Carlson, G. A., & Iadecola, C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.17.9735 · Cited by 244
Mackic, J. B., Stins, M., McComb, J. G., Calero, M., Ghiso, J., Kim, K. S., Yan, S. D., Stern, D., Schmidt, A. M., Frangione, B., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2029 · Cited by 242 · cited 2×
“A later study tested the binding of a radiolabeled Aβ homologue to human endothelial cells in an in vitro AD model and showed that apical binding was significantly downregulated when an anti-RAGE antibody was applied [258].”
BackgroundGlutamatergic systems in Alzheimer's disease
Francis, P. T. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.934 · Cited by 242
“You Shall Not Passâ€â€”tight junctions of the blood brain barrier
Bauer, H.-C., Krizbai, I. A., Bauer, H., & Traweger, A. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00392 · Cited by 241
Emerging Concepts in Alzheimer's Disease
Vinters, H. V. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163927 · Cited by 235
The Diagnosis of Dementia With Single Photon Emission Computed Tomography
Jagust, W. J., Budinger, T. F., & Reed, B. R. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520150014011 · Cited by 234
Evidence for Blood‐Brain Barrier Changes in Senile Dementia of the Alzheimer Type (SDAT)
WISNIEWSKI, H. M., & KOZLOWSKI, P. B. (1982) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1982.tb26848.x · Cited by 234
Endothelial Cell Inflammatory Responses to Tumor Necrosis Factor α
Modur, V., Zimmerman, G. A., Prescott, S. M., & McIntyre, T. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.13094 · Cited by 234
Mayhan, W. G. (1999) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1999.276.5.c1148 · Cited by 233
Targeting Neuroinflammation to Treat Alzheimer’s Disease
Ardura-Fabregat, A., Boddeke, E. W. G. M., Boza-Serrano, A., Brioschi, S., Castro-Gomez, S., Ceyzériat, K., Dansokho, C., Dierkes, T., Gelders, G., Heneka, M. T., et al. (2017) · CNS Drugs · doi:10.1007/s40263-017-0483-3 · Cited by 233
Emerging Therapies for Vascular Dementia and Vascular Cognitive Impairment
Erkinjuntti, T., Román, G., Gauthier, S., Feldman, H., & Rockwood, K. (2004) · Stroke · doi:10.1161/01.str.0000120731.88236.33 · Cited by 232
Vukic, V., Callaghan, D., Walker, D., Lue, L.-F., Liu, Q. Y., Couraud, P.-O., Romero, I. A., Weksler, B., Stanimirovic, D. B., & Zhang, W. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.12.007 · Cited by 232 · cited 1×
“Cerebral endothelial cells in AD are now known to be activated by Aβ1-40 through a JNK-AP1 signalling pathway, causing the upregulated expression of diverse inflammatory mediators including MCP-1, IL-6, IL-8, IL-1β, CXCL1, CXCL2/macrophage inflammatory protein-2α (MIP-2α) and macrophage inflammatory protein-2β (MIP-2β…”
BackgroundAtherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of aging cohort
Dolan, H., Crain, B., Troncoso, J., Resnick, S. M., Zonderman, A. B., & Obrien, R. J. (2010) · Annals of Neurology · doi:10.1002/ana.22055 · Cited by 231
Microglia in Alzheimer’s Disease: Activated, Dysfunctional or Degenerative
Navarro, V., Sanchez-Mejias, E., Jimenez, S., Muñoz-Castro, C., Sanchez-Varo, R., Davila, J. C., Vizuete, M., Gutierrez, A., & Vitorica, J. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00140 · Cited by 229
Schultz, B. G., Patten, D. K., & Berlau, D. J. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0110-3 · Cited by 229
Demonstrating the case that AD is a vascular disease: epidemiologic evidence
LAUNER, L. (2002) · Ageing Research Reviews · doi:10.1016/s0047-6374(01)00364-5 · Cited by 227
Kovac, A., Erickson, M. A., & Banks, W. A. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-139 · Cited by 227
Alzheimer's disease and angiogenesis
Agorogiannis, E. I., & Agorogiannis, G. I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13000-0 · Cited by 224
Distinctive Cognitive Profiles in Alzheimer's Disease and Subcortical Vascular Dementia
Buckley, P. F. (2006) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)70286-x · Cited by 224
Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia
van Oijen, M., Witteman, J. C., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2005) · Stroke · doi:10.1161/01.str.0000189721.31432.26 · Cited by 222
Wisniewski, H. M., Wegiel, J., Wang, K. C., & Lach, B. (1992) · Acta Neuropathologica · doi:10.1007/bf00311383 · Cited by 221
The Effects of Additional Pathology on the Cognitive Deficit in Alzheimer Disease
NAGY, Z., ESIRI, M. M., JOBST, K. A., MORRIS, J. H., -F. KING, E. M., MCDONALD, B., JOACHIM, C., LITCHFIELD, S., BARNETSON, L., & SMITH, A. D. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199702000-00007 · Cited by 218
Giri, R., Shen, Y., Stins, M., Du Yan, S., Schmidt, A. M., Stern, D., Kim, K.-S., Zlokovic, B., & Kalra, V. K. (2000) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2000.279.6.c1772 · Cited by 218
Miyakawa, T., Shimoji, A., Kuramoto, R., & Higuchi, Y. (1982) · Virchows Archiv B Cell Pathology Including Molecular Pathology · doi:10.1007/bf02932857 · Cited by 217
Differential degeneration of the cerebral microvasculature in Alzheimerʼs disease
Kalaria, R. N., & Hedera, P. (1995) · NeuroReport · doi:10.1097/00001756-199502000-00018 · Cited by 216
The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer’s Disease
Hays, C. C., Zlatar, Z. Z., & Wierenga, C. E. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0261-z · Cited by 213
Mattsson, N., Tosun, D., Insel, P. S., Simonson, A., Jack, C. R., Beckett, L. A., Donohue, M., Jagust, W., Schuff, N., & Weiner, M. W. (2014) · Brain · doi:10.1093/brain/awu043 · Cited by 211
LRP1 in Brain Vascular Smooth Muscle Cells Mediates Local Clearance of Alzheimer's Amyloid-β
Kanekiyo, T., Liu, C.-C., Shinohara, M., Li, J., & Bu, G. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.3987-12.2012 · Cited by 211
Claudio, L. (1995) · Acta Neuropathologica · doi:10.1007/s004010050386 · Cited by 210
Chow, N., Bell, R. D., Deane, R., Streb, J. W., Chen, J., Brooks, A., Van Nostrand, W., Miano, J. M., & Zlokovic, B. V. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608251104 · Cited by 209
Noradrenergic dysfunction in Alzheimer's disease
Gannon, M., Che, P., Chen, Y., Jiao, K., Roberson, E. D., & Wang, Q. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00220 · Cited by 209
Alzheimer's disease peptide β-amyloid interacts with fibrinogen and induces its oligomerization
Ahn, H. J., Zamolodchikov, D., Cortes-Canteli, M., Norris, E. H., Glickman, J. F., & Strickland, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010373107 · Cited by 209
APOE ε4 Genotype and Longitudinal Changes in Cerebral Blood Flow in Normal Aging
Thambisetty, M., Beason-Held, L., An, Y., Kraut, M. A., & Resnick, S. M. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.913 · Cited by 209
Towards a Better Understanding of GABAergic Remodeling in Alzheimer’s Disease
Govindpani, K., Calvo-Flores Guzmán, B., Vinnakota, C., Waldvogel, H., Faull, R., & Kwakowsky, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081813 · Cited by 208
Self-citationMiners, J. S., Schulz, I., & Love, S. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17690761 · Cited by 208
Neurovascular unit impairment in early Alzheimer's disease measured with magnetic resonance imaging
van de Haar, H. J., Jansen, J. F. A., van Osch, M. J. P., van Buchem, M. A., Muller, M., Wong, S. M., Hofman, P. A. M., Burgmans, S., Verhey, F. R. J., & Backes, W. H. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.06.006 · Cited by 207
Ruiz, J., Kouiavskaia, D., Migliorini, M., Robinson, S., Saenko, E. L., Gorlatova, N., Li, D., Lawrence, D., Hyman, B. T., Weisgraber, K. H., et al. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500114-jlr200 · Cited by 204
Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease
Bradley, K. M. (2002) · Brain · doi:10.1093/brain/awf185 · Cited by 203
Aβ-peptides enhance vasoconstriction in cerebral circulation
Niwa, K., Porter, V. A., Kazama, K., Cornfield, D., Carlson, G. A., & Iadecola, C. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.281.6.h2417 · Cited by 202
Hippocampal hyperperfusion in Alzheimer's disease
Alsop, D. C., Casement, M., de Bazelaire, C., Fong, T., & Press, D. Z. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.06.006 · Cited by 202
Takata, F., Dohgu, S., Matsumoto, J., Takahashi, H., Machida, T., Wakigawa, T., Harada, E., Miyaji, H., Koga, M., Nishioku, T., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-106 · Cited by 202
Schuff, N., Matsumoto, S., Kmiecik, J., Studholme, C., Du, A., Ezekiel, F., Miller, B. L., Kramer, J. H., Jagust, W. J., Chui, H. C., et al. (2009) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2009.04.1233 · Cited by 200
GLUT-1 Expression in the Cerebra of Patients with Alzheimer’s Disease
Mooradian, A. D., Chung, H. C., & Shah, G. N. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00111-5 · Cited by 199
Differential effects of the APOE genotype on brain function across the lifespan
Filippini, N., Ebmeier, K. P., MacIntosh, B. J., Trachtenberg, A. J., Frisoni, G. B., Wilcock, G. K., Beckmann, C. F., Smith, S. M., Matthews, P. M., & Mackay, C. E. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.08.009 · Cited by 196
Immunotherapy for Alzheimer’s disease: hoops and hurdles
Lemere, C. A. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-36 · Cited by 196
Cited by
The interplay between diet and the gut microbiome: implications for health and disease
Ross, F. C., Patangia, D., Grimaud, G., Lavelle, A., Dempsey, E. M., Ross, R. P., & Stanton, C. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01068-4 · Cited by 638
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Neurovascular Unit Dysfunction and Neurodegenerative Disorders
Yu, X., Ji, C., & Shao, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00334 · Cited by 244
Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00339 · Cited by 170
Cummings, J. L., Atri, A., Feldman, H. H., Hansson, O., Sano, M., Knop, F. K., Johannsen, P., León, T., & Scheltens, P. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01666-7 · Cited by 168
Metadata
- Authors
- Govindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L., & Kwakowsky, A.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2019-05-10
- Volume
- 8
- Issue
- 5
- Pages
- 651
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2946791655
- Cited by
- 275
- References
- 471
- FWCI
- 13.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.